RX-0301

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameRX-0301
Drug Alias NameMychexinRX-0201 nanoliposomalRX-0201 NanoRX-0201-NRX-0301 +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitors
TargetsSerine/threonine-protein kinase AKT1
Therapy Area/IndicationsSolid tumoursLiver NeoplasmsCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesHong KongMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRexahn Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhejiang Haichang Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLiver NeoplasmsCarcinoma, Renal Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A